How Can We Help?
You are here:
< Back

Myxothiazol is a chemical compound produced by the myxobacterium Myxococcus fulvus. It is an inhibitor of the mitochondrial cytochrome bc1 complex (coenzyme Q - cytochrome c reductase).[1][2]

Myxothiazol is a competitive inhibitor of ubiquinol, and binds at the quinol oxidation (Qo) site of the bc1 complex, blocking electron transfer to the Rieske iron-sulfur protein. Binding of myxothiazol induces a red-shift to the visible absorption spectrum of reduced haem bl. In contrast to stigmatellin, myxothiazol does not form a hydrogen bond to the Rieske iron-sulfur protein, binding instead in the 'b-proximal' region of the cytochrome b Qo site. Movement of the cytoplasmic domain of the Rieske protein is therefore unaffected by the binding of this inhibitor.[citation needed]

References

  1. ^ Georg Thierbach, Hans Reichenbach (1981). "Myxothiazol, a new antibiotic interfering with respiration". Antimicrobial Agents and Chemotherapy. 19 (4): 504–507. doi:10.1128/AAC.19.4.504. PMC 181466. PMID 7247372.
  2. ^ Gebhard von Jagow, W. D. Engel (1981). "Complete Inhibition of Electron Transfer from Ubiquinol to Cytochrome by the Combined Action of Antimycin and Myxothiazol". FEBS Letters. 136 (1): 19–24. doi:10.1016/0014-5793(81)81206-9. PMID 7319059.
Categories
Table of Contents